Jed E. Rose
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Jed E. Rose has a total of 47 co-authors. Here are the top co-authors by number of shared publications:
Frederique M. Behm
Department of Psychiatry, Duke University Medical Center Durham, NC
5 shared publicationsDawn Lawhon
Department of Psychiatry, Duke University Medical Center Durham, NC
3 shared publicationsFrederique M Behm
3 shared publicationsKevin Calkins
Department of Psychiatry, Duke University Medical Center Durham, NC
3 shared publicationsMatthew Cramblett
Department of Psychiatry, Duke University Medical Center Durham, NC
3 shared publicationsD. L. Mohr
National Bureau of Standards
2 shared publications
Latest Publications
- 1 February 2004
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 6 (1) , 133-144
Psychopharmacological interactions between nicotine and ethanol
Epidemiological, clinical, and laboratory evidence has shown a positive correlation between cigarette smoking and ethanol use, and previous studies suggest some commonality in the neural pathways mediating effects of nicotine and ethanol. In this study, the subjective and behavioral interactions among nicotine, ethanol, and the nicotinic antagonist mecamylamine were investigated. The main objectives were to determine how the rewarding effects of nicotine might be modified by ethanol, and to compare the effects of ethanol with those of a nicotinic antagonist (mecamylamine). A total of 48 smokers who regularly consumed alcoholic beverages participated in four laboratory sessions presenting a 2 (nicotine vs. denicotinized cigarette smoke)×2 (10 mg oral mecamylamine hydrochloride vs. placebo)×2 (ethanol .5 g/kg vs. placebo) design, with ethanol as a between-subjects factor. Dependent measures included blood alcohol concentration (BAC), as assessed by breath alcohol detector; subjective drug effects; and rate of ad lib smoking during a 2-hr period. Results showed that peak BAC averaged .03 g/dl in the ethanol condition. Ethanol potentiated some of the subjective rewarding effects of nicotine, including smoking satisfaction, stimulant as well as calming effects, and relief of craving for cigarettes. During the ad lib smoking period, mecamylamine decreased satisfaction associated with the nicotine-containing cigarettes; mecamylamine also induced smoking but only in the placebo ethanol condition. These results highlight the potent interaction between ethanol and nicotinic systems, and suggest that ethanol can potentiate the rewarding effects of nicotine as well as offset some of the effects of a nicotinic antagonist.
- 1 February 2004
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 6 (1) , 133-144
Psychopharmacological interactions between nicotine and ethanol
Epidemiological, clinical, and laboratory evidence has shown a positive correlation between cigarette smoking and ethanol use, and previous studies suggest some commonality in the neural pathways mediating effects of nicotine and ethanol. In this study, the subjective and behavioral interactions among nicotine, ethanol, and the nicotinic antagonist mecamylamine were investigated. The main objectives were to determine how the rewarding effects of nicotine might be modified by ethanol, and to compare the effects of ethanol with those of a nicotinic antagonist (mecamylamine). A total of 48 smokers who regularly consumed alcoholic beverages participated in four laboratory sessions presenting a 2 (nicotine vs. denicotinized cigarette smoke)×2 (10 mg oral mecamylamine hydrochloride vs. placebo)×2 (ethanol .5 g/kg vs. placebo) design, with ethanol as a between-subjects factor. Dependent measures included blood alcohol concentration (BAC), as assessed by breath alcohol detector; subjective drug effects; and rate of ad lib smoking during a 2-hr period. Results showed that peak BAC averaged .03 g/dl in the ethanol condition. Ethanol potentiated some of the subjective rewarding effects of nicotine, including smoking satisfaction, stimulant as well as calming effects, and relief of craving for cigarettes. During the ad lib smoking period, mecamylamine decreased satisfaction associated with the nicotine-containing cigarettes; mecamylamine also induced smoking but only in the placebo ethanol condition. These results highlight the potent interaction between ethanol and nicotinic systems, and suggest that ethanol can potentiate the rewarding effects of nicotine as well as offset some of the effects of a nicotinic antagonist.
- 1 February 2003
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 160 (2) , 323-333
PET Studies of the Influences of Nicotine on Neural Systems in Cigarette Smokers
OBJECTIVE: The effects of acute nicotine administration and smoking on brain function were investigated in two studies, with the primary goal of identifying neural systems that mediate these effects. METHOD: In study 1, 18 healthy volunteer cigarette smokers were exposed to three conditions in a single session: 1) smoking a nicotine-containing cigarette, 2) smoking a denicotinized cigarette, or 3) receiving intravenous nicotine injections in conjunction with smoking a denicotinized cigarette. In study 2, 16 subjects smoked a nicotine-containing and denicotinized cigarette in each of two sessions 2 hours after receiving the nicotinic antagonist mecamylamine (10 mg) or placebo orally. Regional cerebral blood flow (rCBF) was assessed by using the bolus 15O-labeled water method and positron emission tomography. Subjective measures of smoking withdrawal symptoms were also collected. RESULTS: A principal-components analysis of rCBF data pooled from the two studies identified three factors consisting of frontal,...
- 1 February 2003
- Published by American Psychiatric Association Publishing in American Journal of Psychiatry
- Vol. 160 (2) , 323-333
PET Studies of the Influences of Nicotine on Neural Systems in Cigarette Smokers
OBJECTIVE: The effects of acute nicotine administration and smoking on brain function were investigated in two studies, with the primary goal of identifying neural systems that mediate these effects. METHOD: In study 1, 18 healthy volunteer cigarette smokers were exposed to three conditions in a single session: 1) smoking a nicotine-containing cigarette, 2) smoking a denicotinized cigarette, or 3) receiving intravenous nicotine injections in conjunction with smoking a denicotinized cigarette. In study 2, 16 subjects smoked a nicotine-containing and denicotinized cigarette in each of two sessions 2 hours after receiving the nicotinic antagonist mecamylamine (10 mg) or placebo orally. Regional cerebral blood flow (rCBF) was assessed by using the bolus 15O-labeled water method and positron emission tomography. Subjective measures of smoking withdrawal symptoms were also collected. RESULTS: A principal-components analysis of rCBF data pooled from the two studies identified three factors consisting of frontal,...
- 1 December 2002
- Published by Rockefeller University Press
- Vol. 26 (12) , 1930-1
Potentiation of nicotine reward by alcohol.
- 1 December 2002
- Published by Rockefeller University Press
- Vol. 26 (12) , 1930-1
Potentiation of nicotine reward by alcohol.
- 1 December 2002
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 26 (12) , 1930-1931
Potentiation of Nicotine Reward by Alcohol
- 1 December 2002
- Published by Wiley in Alcohol, Clinical and Experimental Research
- Vol. 26 (12) , 1930-1931
Potentiation of Nicotine Reward by Alcohol
- 1 November 2001
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 3 (4) , 383-390
Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms
Previous studies have found that constituents in tobacco inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B). This enzyme is important in the breakdown of the amine neurotransmitters, including dopamine, which is thought to mediate the reinforcing effects of nicotine and contribute to tobacco dependence. To further examine the relationship between cigarette smoking, smoking cessation and MAO, we measured platelet MAO-B activity in 16 smokers before and after being switched to smoking denicotinized cigarettes; in a subset of six subjects who subsequently quit-smoking, MAO-B activity was also measured at 1 and 4 weeks following cessation. Smoking cessation treatment was provided in an open-label format, and included nicotine skin patch treatment in conjunction with oral mecamylamine (a nicotinic antagonist) and neostigmine (a peripherally acting acetylcholinesterase inhibitor, administered to counteract constipation experienced from mecamylamine). Results showed that smoking behavior, indexed by expired air carbon monoxide levels, was negatively correlated with platelet MAO-B activity prior to smoking cessation. Moreover, MAO-B activity significantly increased by approximately 100% at 4 weeks after quitting smoking. However, little or no recovery occurred within the first week of abstinence, suggesting that the constituents in tobacco responsible for MAO inhibition may have half-lives of several days. Thus, if relapse to smoking is due in part to withdrawal from the MAO-inhibiting effects of tobacco, this effect likely occurs more than 1 week after quitting. Additionally, low baseline MAO-B activity significantly predicted the intensity of withdrawal symptoms reported upon switching to the denicotinized cigarettes as well as after smoking cessation. These results support the view that MAO inhibition from non-nicotine constituents in cigarette smoke is relevant to tobacco dependence and that continued investigation of the potential use of MAO inhibitors in smoking cessation treatment is warranted.
- 1 November 2001
- Published by Oxford University Press (OUP) in Nicotine & Tobacco Research
- Vol. 3 (4) , 383-390
Platelet monoamine oxidase, smoking cessation, and tobacco withdrawal symptoms
Previous studies have found that constituents in tobacco inhibit both forms of the enzyme monoamine oxidase (MAO-A and MAO-B). This enzyme is important in the breakdown of the amine neurotransmitters, including dopamine, which is thought to mediate the reinforcing effects of nicotine and contribute to tobacco dependence. To further examine the relationship between cigarette smoking, smoking cessation and MAO, we measured platelet MAO-B activity in 16 smokers before and after being switched to smoking denicotinized cigarettes; in a subset of six subjects who subsequently quit-smoking, MAO-B activity was also measured at 1 and 4 weeks following cessation. Smoking cessation treatment was provided in an open-label format, and included nicotine skin patch treatment in conjunction with oral mecamylamine (a nicotinic antagonist) and neostigmine (a peripherally acting acetylcholinesterase inhibitor, administered to counteract constipation experienced from mecamylamine). Results showed that smoking behavior, indexed by expired air carbon monoxide levels, was negatively correlated with platelet MAO-B activity prior to smoking cessation. Moreover, MAO-B activity significantly increased by approximately 100% at 4 weeks after quitting smoking. However, little or no recovery occurred within the first week of abstinence, suggesting that the constituents in tobacco responsible for MAO inhibition may have half-lives of several days. Thus, if relapse to smoking is due in part to withdrawal from the MAO-inhibiting effects of tobacco, this effect likely occurs more than 1 week after quitting. Additionally, low baseline MAO-B activity significantly predicted the intensity of withdrawal symptoms reported upon switching to the denicotinized cigarettes as well as after smoking cessation. These results support the view that MAO inhibition from non-nicotine constituents in cigarette smoke is relevant to tobacco dependence and that continued investigation of the potential use of MAO inhibitors in smoking cessation treatment is warranted.
- 1 February 2001
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 68 (2) , 187-197
Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking
- 1 February 2001
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 68 (2) , 187-197
Acute effects of nicotine and mecamylamine on tobacco withdrawal symptoms, cigarette reward and ad lib smoking
- 1 September 2000
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 67 (1) , 71-81
Dissociating nicotine and nonnicotine components of cigarette smoking
- 1 September 2000
- Published by Elsevier in Pharmacology Biochemistry and Behavior
- Vol. 67 (1) , 71-81
Dissociating nicotine and nonnicotine components of cigarette smoking
- 1 September 1999
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 56 (2) , 99-107
Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction
- 1 September 1999
- Published by Elsevier in Drug and Alcohol Dependence
- Vol. 56 (2) , 99-107
Arterial nicotine kinetics during cigarette smoking and intravenous nicotine administration: implications for addiction
- 1 January 1998
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 6 (3) , 331-343
Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.
The nicotinic antagonist mecamylamine was evaluated in a randomized smoking cessation trial. Four groups of participants (n = 20 per group) received nicotine plus mecamylamine, nicotine alone, mecamylamine alone, or no drug for 4 weeks before cessation. After the quit-smoking date, all subjects received nicotine plus mecamylamine treatment for 6 weeks. Nicotine skin patches (21 mg/24 hr) and mecamylamine capsules (2.5-5.0 mg twice per day) were used. Precessation mecamylamine significantly prolonged the duration of continuous smoking abstinence; abstinence rates at the end of treatment were 47.5% with mecamylamine and 27.5% without mecamylamine. Nicotine + mecamylamine reduced ad lib smoking, smoking satisfaction, and craving more than either drug alone. Moreover, the orthostatic decrease in blood pressure caused by mecamylamine was offset by nicotine. Mecamylamine before smoking cessation may be an effective adjunct to nicotine patch therapy.
- 1 January 1998
- Published by American Psychological Association (APA) in Experimental and Clinical Psychopharmacology
- Vol. 6 (3) , 331-343
Nicotine-mecamylamine treatment for smoking cessation: The role of pre-cessation therapy.
The nicotinic antagonist mecamylamine was evaluated in a randomized smoking cessation trial. Four groups of participants (n = 20 per group) received nicotine plus mecamylamine, nicotine alone, mecamylamine alone, or no drug for 4 weeks before cessation. After the quit-smoking date, all subjects received nicotine plus mecamylamine treatment for 6 weeks. Nicotine skin patches (21 mg/24 hr) and mecamylamine capsules (2.5-5.0 mg twice per day) were used. Precessation mecamylamine significantly prolonged the duration of continuous smoking abstinence; abstinence rates at the end of treatment were 47.5% with mecamylamine and 27.5% without mecamylamine. Nicotine + mecamylamine reduced ad lib smoking, smoking satisfaction, and craving more than either drug alone. Moreover, the orthostatic decrease in blood pressure caused by mecamylamine was offset by nicotine. Mecamylamine before smoking cessation may be an effective adjunct to nicotine patch therapy.